Genentech panel convenes; Roche's bid under scrutiny
This article was originally published in Scrip
Executive Summary
It appears thatRoche, with its July 21st offer to buy the 44% of Genentechthat it does not already own, could face a bumpy road ahead. Genentech now says that it won't approve a merger until the deal gains "a favourable recommendation" from a special committee of its three independent board members, all non-Roche employees.